Addex Therapeutics (ADXN) Net Margin (2019 - 2025)
Addex Therapeutics (ADXN) posted Net Margin of 2759108.04% for Q4 2025, down 8201172750940.32% sequentially from 0.0% in Q3 2025, and down 340081892.0% YoY from N/an in Q4 2024.
Addex Therapeutics (ADXN) Net Margin (2019 - 2025) Analysis & Trends
Addex Therapeutics has reported Net Margin for 7 years, with the latest figure at 2759108.04% in Q4 2025.
- Quarterly Net Margin fell 340081892.0% year-over-year to 2759108.04% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 21845.49% (down 2425305.0% YoY) and the FY2025 annual result came in at 22829.93%, down 2457598.0% from the prior year.
- Net Margin eased to 2759108.04% in Q4 2025 per ADXN's latest filing, from 0.0% in the prior quarter.
- Over five years, Net Margin peaked at 641710.88% in Q4 2024 and troughed at 2759108.04% in Q4 2025.
- A 5-year average of 117734.62% and a median of 0.0% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin jumped 64096471 bps in 2024, then plunged 340081892 bps in 2025.
- Over 5 years, Net Margin stood at 536.98% in 2021, then surged by 54 bps to 829.3% in 2022, then retreated by 10 bps to 746.17% in 2023, then soared by 85901 bps to 641710.88% in 2024, then slumped by 530 bps to 2759108.04% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 2759108.04%, 0.0%, and 641710.88% for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Addex Therapeutics | 515.38 Mn | 515.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2,759,108.04% |
| Sep 30, 2025 | 0.00% |
| Dec 31, 2024 | 641,710.88% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 746.17% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 829.30% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | -3,938.42% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 536.98% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 0.00% |
| Mar 31, 2021 | 0.00% |
| Dec 31, 2020 | 376.64% |
| Sep 30, 2020 | 0.00% |